CIK 0001439222 · Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-02 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise 10b5-1 | +2,450 | 4,970 | ||
| 2026-03-02 | Washburn Theodore James Jr. Principal Accounting Officer | Sale 10b5-1 | −727 | $28.96 | $21K | 4,243 |
| 2026-03-02 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise 10b5-1 | +2,695 | 6,938 | ||
| 2026-03-02 | Washburn Theodore James Jr. Principal Accounting Officer | Sale 10b5-1 | −798 | $28.96 | $23K | 6,140 |
| 2026-03-02 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise · Restricted stock units 10b5-1 | −2,350 | 0 | ||
| 2026-03-02 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise · Restricted stock units 10b5-1 | −2,450 | 2,450 | ||
| 2026-03-02 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise · Restricted stock units 10b5-1 | −2,695 | 5,390 | ||
| 2026-03-01 | Goff Brian Chief Executive Officer | Grant or award · Restricted stock units 10b5-1 | +48,000 | 48,000 | ||
| 2026-03-01 | Goff Brian Chief Executive Officer | Grant or award · Stock options (right to buy) 10b5-1 | +174,000 | 174,000 | ||
| 2026-03-01 | Burns James William Chief Legal Officer | Grant or award · Restricted stock units 10b5-1 | +14,000 | 14,000 | ||
| 2026-03-01 | Burns James William Chief Legal Officer | Grant or award · Stock options (right to buy) 10b5-1 | +52,000 | 52,000 | ||
| 2026-03-01 | Gheuens Sarah Chief Medical Officer | Grant or award · Restricted stock units 10b5-1 | +14,000 | 14,000 | ||
| 2026-03-01 | Gheuens Sarah Chief Medical Officer | Grant or award · Restricted stock units 10b5-1 | +22,000 | 22,000 | ||
| 2026-03-01 | Gheuens Sarah Chief Medical Officer | Grant or award · Stock options (right to buy) 10b5-1 | +52,000 | 52,000 | ||
| 2026-03-01 | Jones Cecilia Chief Financial Officer | Grant or award · Restricted stock units 10b5-1 | +14,000 | 14,000 | ||
| 2026-03-01 | Jones Cecilia Chief Financial Officer | Grant or award · Stock options (right to buy) 10b5-1 | +52,000 | 52,000 | ||
| 2026-03-01 | Milanova Tsveta Chief Commercial Officer | Grant or award · Restricted stock units 10b5-1 | +14,000 | 14,000 | ||
| 2026-03-01 | Milanova Tsveta Chief Commercial Officer | Grant or award · Stock options (right to buy) 10b5-1 | +52,000 | 52,000 | ||
| 2026-03-01 | Washburn Theodore James Jr. Principal Accounting Officer | Grant or award · Restricted stock units 10b5-1 | +8,452 | 8,452 | ||
| 2026-03-01 | Viswanadhan Krishnan Chief Corp Dev & Strategy | Grant or award · Restricted stock units 10b5-1 | +14,000 | 14,000 |
Page 8 of 48 · 941 trades